Klrb1-KO Mouse
一般名
Klrb1-KO
製品ID
S-KO-00056
背景情報
C57BL/6NCya
系統ID
KOCMP-100043861-Klrb1-B6N-VA
状況
このマウス系統を論文で使用する場合は、「Klrb1-KO Mouse（カタログ番号S-KO-00056）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Klrb1-KO
系統ID
KOCMP-100043861-Klrb1-B6N-VA
遺伝子名
製品ID
S-KO-00056
遺伝子別名
Ly55, Klrb6, Ly-55, Gm4696, Klrb1g, Nkrp1g, NKR-P1G, Nkrp-1e, 4930431A04Rik
遺伝子別名
C57BL/6NCya
NCBI ID
修正
Conventional knockout
染色体
Chr 6
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000112110
NCBIトランスクリプトID
NM_001099918
ターゲット領域
Exon 2~5
有効領域の大きさ
~3.6 kb
遺伝子研究の概要
Klrb1, also known as CD161, encodes an inhibitory receptor expressed on various immune cells and is involved in immune checkpoint regulation [7]. It has been implicated in multiple biological processes related to immunity and may influence immune cell-mediated killing of tumor cells, thus affecting tumor progression [4,5].
In glioma, CD161 was enriched in high-grade and IDH-wildtype gliomas, acting as a biomarker for the mesenchymal subtype and an independent prognostic factor. It inhibited T-cell cytotoxicity, and its expression dynamically evolved during gliomagenesis, promoting glioma progression [1]. In early-relapse hepatocellular carcinoma, CD8+ T cells in recurrent tumors overexpressed Klrb1 (CD161) and displayed a low-cytotoxic state, associated with a worse prognosis [2]. Genetic inactivation of Klrb1 enhanced T-cell-mediated killing of glioma cells in vitro and anti-tumor function in vivo [3]. In breast invasive carcinoma, decreased Klrb1 expression was associated with poor prognosis, increased tumor cell proliferation, migration, and invasion, and was related to the immune microenvironment [8]. In lung adenocarcinoma, Klrb1 expression was lower in cancer tissue, affected immune-related pathways and the MAPK/ERK signaling pathway, thus modulating cell growth and proliferation [6]. Klrb1 knockout in mice disrupted immune and metabolic functions in the liver, potentially leading to chronic inflammation and malignancy risks [7].
In summary, Klrb1 plays a crucial role in immune-related biological processes, especially in the context of various cancers and liver diseases. Gene knockout models, such as the Klrb1 KO mouse model, have been instrumental in revealing its functions in these disease conditions, highlighting its potential as a therapeutic target and biomarker.
References:
1. Di, Wang, Fan, Wenhua, Wu, Fan, Kahlert, Ulf Dietrich, Zhang, Wei. 2021. Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples. In Cancer science, 113, 756-769. doi:10.1111/cas.15236. https://pubmed.ncbi.nlm.nih.gov/34881489/
2. Sun, Yunfan, Wu, Liang, Zhong, Yu, Yang, Xinrong, Fan, Jia. 2020. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. In Cell, 184, 404-421.e16. doi:10.1016/j.cell.2020.11.041. https://pubmed.ncbi.nlm.nih.gov/33357445/
3. Mathewson, Nathan D, Ashenberg, Orr, Tirosh, Itay, Suvà, Mario L, Wucherpfennig, Kai W. 2021. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. In Cell, 184, 1281-1298.e26. doi:10.1016/j.cell.2021.01.022. https://pubmed.ncbi.nlm.nih.gov/33592174/
4. Liang, Chunyun, Chen, Yue, Chen, Si, Shi, Qiuyan, Wang, Peijuan. 2023. KLRB1 is a novel prognostic biomarker in endometrial cancer and is associated with immune infiltration. In Translational cancer research, 12, 3641-3652. doi:10.21037/tcr-23-697. https://pubmed.ncbi.nlm.nih.gov/38192989/
5. Zhu, Yaoyao, Zhang, Huajie, Shao, Ruoyang, Lu, Peiyuan, Ma, Zhongrui. 2024. Comprehensive pan-cancer analysis of KLRB1-CLEC2D pair and identification of small molecule inhibitors to disrupt their interaction. In International immunopharmacology, 140, 112908. doi:10.1016/j.intimp.2024.112908. https://pubmed.ncbi.nlm.nih.gov/39133960/
6. Xu, Siwei, Xu, Yujian, Chai, Wenjun, Pan, Hongyu, Yan, Mingxia. 2024. KLRB1 expression is associated with lung adenocarcinoma prognosis and immune infiltration and regulates lung adenocarcinoma cell proliferation and metastasis through the MAPK/ERK pathway. In Journal of thoracic disease, 16, 3764-3781. doi:10.21037/jtd-24-8. https://pubmed.ncbi.nlm.nih.gov/38983163/
7. Yang, Shuqi, Luo, Tingting, Liu, Haoran, Li, Mingzhou, Lu, Lu. 2024. Klrb1 Loss Promotes Chronic Hepatic Inflammation and Metabolic Dysregulation. In Genes, 15, . doi:10.3390/genes15111444. https://pubmed.ncbi.nlm.nih.gov/39596644/
8. He, Jin-Rong, Li, Dan, Zhang, Qun-Xian, Chen, Shan-Shan, Chen, Jiu-Ling. 2023. Inhibiting KLRB1 expression is associated with impairing cancer immunity and leading to cancer progression and poor prognosis in breast invasive carcinoma patients. In Aging, 15, 13265-13286. doi:10.18632/aging.205239. https://pubmed.ncbi.nlm.nih.gov/37988189/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。